论文部分内容阅读
目的:探讨长春瑞滨联合卡铂治疗非小细胞肺癌的临床疗效及安全性。方法:将60例非小细胞肺癌患者随机分为观察组(30例)和对照组(30例),观察组采用长春瑞滨联合卡铂治疗,对照组采用多西紫杉醇治疗。观察疗效及不良反应,2个周期后比较疗效。结果:观察组患者总有效率为53.3%(16/30),对照组为26.7%(18/30),二者差异有显著性(P<0.05);不良反应主要有骨髓抑制、脱发、粒细胞减少性发热、乏力和消化道反应。结论:长春瑞滨联合卡铂治疗非小细胞肺癌的临床疗效较高,且患者可以耐受毒性,值得临床推广应用。
Objective: To investigate the clinical efficacy and safety of vinorelbine plus carboplatin in the treatment of non-small cell lung cancer. Methods: Sixty non-small cell lung cancer patients were randomly divided into the observation group (30 cases) and the control group (30 cases). The observation group was treated with vinorelbine plus carboplatin. The control group was treated with docetaxel. Observation of efficacy and adverse reactions, more effective after 2 cycles. Results: The total effective rate was 53.3% (16/30) in the observation group and 26.7% (18/30) in the control group, with significant difference between the two groups (P <0.05). Adverse reactions included bone marrow suppression, alopecia, Decreased cellular fever, fatigue and digestive tract reactions. Conclusion: Vinorelbine combined with carboplatin in the treatment of non-small cell lung cancer has high clinical efficacy, and patients can tolerate toxicity, it is worthy of clinical application.